Catalyst Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Catalyst Pharmaceuticals's estimated annual revenue is currently $34.8M per year.
- Catalyst Pharmaceuticals's estimated revenue per employee is $201,000
Employee Data
- Catalyst Pharmaceuticals has 173 Employees.
- Catalyst Pharmaceuticals grew their employee count by 77% last year.
Catalyst Pharmaceuticals's People
Name | Title | Email/Phone |
---|---|---|
1 | Chief Strategy Officer | Reveal Email/Phone |
2 | EVP and CFO | Reveal Email/Phone |
3 | VP, Finance & Reporting | Reveal Email/Phone |
4 | SVP Marketing | Reveal Email/Phone |
5 | VP, Patient Services | Reveal Email/Phone |
6 | Controller | Reveal Email/Phone |
7 | SVP Medical Affairs and Drug Discovery | Reveal Email/Phone |
8 | Director Financial Planning and Analysis | Reveal Email/Phone |
9 | Director, PV Operations | Reveal Email/Phone |
10 | Sr. Director, Commercial Operations and Marketing | Reveal Email/Phone |
Catalyst Pharmaceuticals Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $26.5M | 132 | N/A | N/A | N/A |
#2 | $10.1M | 50 | 14% | N/A | N/A |
#3 | $282.6M | 1406 | N/A | N/A | N/A |
#4 | $13.9M | 69 | 44% | N/A | N/A |
#5 | $11.3M | 56 | 4% | N/A | N/A |
#6 | $11.5M | 57 | -7% | N/A | N/A |
#7 | $211.7M | 1072 | 4% | N/A | N/A |
#8 | $24.1M | 120 | 5% | N/A | N/A |
#9 | $7.8M | 39 | -2% | N/A | N/A |
#10 | $12.9M | 64 | -2% | N/A | N/A |
What Is Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis (MuSK-MG) and spinal muscular atrophy (SMA) Type 3. Catalyst's new drug application for Firdapse® (amifampridine) 10 mg tablets for the treatment of adults with LEMS was recently approved by the U.S. Food & Drug Administration ("FDA"), and Firdapse is now commercially available in the United States. Prior to its approval, Firdapse for LEMS had received breakthrough therapy designation and orphan drug designation from the FDA. Firdapse is currently being evaluated in clinical trials for the treatment of CMS, MuSK-MG and SMA Type 3 and has received Orphan Drug Designation from the FDA for CMS and myasthenia gravis. Firdapse (amifampridine) 10 mg tablets is the first and only approved drug in Europe for the symptomatic treatment in adults with LEMS.
keywords:N/AN/A
Total Funding
173
Number of Employees
$34.8M
Revenue (est)
77%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Catalyst Pharmaceuticals News
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel...
Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with...
Shares of Catalyst Pharmaceuticals Inc. CPRX, -2.72% slipped 2.72% to $8.24 Thursday, on what proved to be an all-around dismal trading...
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX)'s share price reached a new 52-week high on Friday . The stock traded as high as $6.69 and ...
Intraday Trading of Catalyst Pharmaceuticals, Inc.: If one intends to pursue a career as a trader, then one must understand and choose between ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $28.9M | 181 | N/A | N/A |
#2 | $35M | 207 | -21% | N/A |
#3 | $56M | 207 | 9% | N/A |
#4 | N/A | 212 | 136% | N/A |
#5 | $15M | 216 | 11% | N/A |